trial

Efficacy and Tolerability of Flunarizine for the Treatment of Schizophrenia: Comparison With Haloperidol

NCTId NCT00740259
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 70 (actual)
Sponsored by Ambulatório de Bipolaridade
Primary completion 2007-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
70 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2004-09
Primary completion
2007-05
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Flunarizine

Sponsors

Ambulatório de BipolaridadeLead Sponsor
Stanley Medical Research InstituteCollaborator

Sites

1 total
São Paulo, Brazil

Facts & assertions

4 sourced
Enrollment
70
Phase
PHASE4
Primary Completion Date
2007-05
Status
COMPLETED
relationships
The graph out of here
drug
Flunarizine
drug
lead_sponsor
Ambulatório de Bipolaridade
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizophrenia
indication